Antiretroviral and Antituberculosis therapy in HIV-TB co-infected children

Journal Title
Journal ISSN
Volume Title
HIV-infected children experience a high burden of tuberculosis. With recent advances in international pediatric HIV treatment guidelines significant numbers of infants and children will require simultaneous treatment for both TB and HIV. This article attempts to concisely outline strategies for effective co-treatment of both infections. Rifamycins, an essential component of short course TB chemotherapy, alter the metabolism of a number of antiretroviral drugs. These interactions and their consequences are considered. Options for antiretroviral therapy and the optimal timing of its initiation in the presence of antituberculosis therapy are discussed. © 2011 Bentham Science Publishers Ltd.
Antiretroviral therapy, Antituberculosis therapy, Children, TB-HIV co-infection, abacavir, cotrimoxazole, didanosine, efavirenz, ethambutol, isoniazid, lopinavir, nevirapine, proteinase inhibitor, pyrazinamide, pyridoxine, rifabutin, rifampicin, rifamycin, rifapentine, ritonavir, stavudine, streptomycin, zidovudine, anemia, central nervous system disease, combination chemotherapy, drug blood level, drug clearance, drug dose escalation, drug efficacy, drug metabolism, drug safety, drug tolerance, highly active antiretroviral therapy, human, Human immunodeficiency virus infection, liver toxicity, mixed infection, nausea and vomiting, neutropenia, outcome assessment, pediatrics, peripheral neuropathy, priority journal, rash, recommended drug dose, review, treatment indication, tuberculosis
Current Pediatric Reviews